Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population (n = 74)

From: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes

Variables Placebo N = 38 n-3 PUFAs N = 36
Age (years) 66.7 (±6.8) 64.4 (±6.7)
Female sex, n (%) 12 (31.6) 14 (38.9)
Hypertension, n (%) 36 (93.7) 36 (100)
Hyperlipidemia, n (%) 22 (57.9) 28 (77.8)
Metabolic syndrome, n (%) 38 (100) 36 (100)
Obesity, n (%) 25 (65.8) 23 (63.9)
Waist circumference (cm) 107 (98; 113) 106 (99; 112)
Body mass index (kg/m2) 31.1 (28.1; 32.7) 30.9 (27.9; 34.7)
Body fat (%) 30.4 (27.4; 35.8) 34.0 (31.0; 43.0)
Visceral fat (%) 15.74 (±4.9) 16.25 (±4.5)
Total body water (%) 47.9 (43.9; 49.8) 47.5 (44.2; 49.2)
Muscle mass (kg) 53.5 (±11.5) 56.85 (±9.2)
DM2 duration (years) 10 (6; 15) 10 (6.5; 15)
CAD, n (%) 38 (100) 36 (100)
PAD, n (%) 14 (38.9) 12 (31.3)
Previous MI, n (%) 16 (42.1) 12 (33.3)
Previous PCI, n (%) 25 (65.8) 22 (61.1)
Creatinine (μmol/L) 84 (66; 94) 86.5 (74; 100)
eGFR (MDRD) (mL/min/1.73 m2) 78.6 (70; 90) 78 (69; 89)
Treatment, n (%)
 Beta blocker 31 (81.6) 30 (83.3)
 ACEI or ARB 33 (86.8) 34 (94.4)
 Long acting nitrate 5 (13.2) 6 (16.7)
 Calcium antagonist 13 (34.2) 19 (52.8)
 Statin 33 (86.8) 35 (97.2)
 Fibrate 0 1 (2.78)
 ASA 38 (100) 36 (100)
 Clopidogrel 19 (50) 14 (38.9)
 Metformin 24 (63.2) 25 (69.4)
 Sulfonylurea 14 (36.8) 17 (47.2)
 Acarbose 1 (2.6) 2 (5.6)
 DPP-IV 1 (2.6) 0
 Insulin 16 (42.1) 16 (44.4)
 PPI 10 (26.3) 12 (33.3)
 Loop diuretic 6 (15.8) 3 (8.3)
 Diuretic 11 (28.9) 11 (30.6)
 AA 6 (15.8) 3 (8.3)
  1. Data shown as number (percentage) for categorical variables and mean (±standard deviation) or median (IQR) for continuous variables
  2. CAD coronary artery disease, PAD peripheral artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, eGFR (MDRD) estimated glomerular filtration rate calculated by the abbreviated MDRD equation, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, ASA acetylsalicylic acid, PPI proton pump inhibitors, AA aldosterone antagonist